Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

This study is testing a novel vaccine-based treatment combined with immunotherapy (anti-PD-1) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) — cancers affecting the throat, mouth, or voice box that have come back or spread. The vaccine is designed to stimulate the immune system to attack the cancer. **You may be eligible if:** - You have confirmed recurrent or metastatic head and neck squamous cell carcinoma - You are 18 or older - Your general health score (ECOG) is 0-2 - Your blood counts, kidney, and liver function meet required levels - If you have Hepatitis B, C, or HIV, your viral levels must be well-controlled **You may NOT be eligible if:** - You have active autoimmune disease requiring treatment - You are pregnant or breastfeeding - You have active, untreated brain metastases - You have severe organ failure (liver, kidneys, heart) - You are not expected to survive more than 3 months Talk to your doctor to see if this trial is right for you.